Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9852425 | 0.84 | SMN1; SMN2 (0.38) | SMN1; SMN2GAACYP3A4 | |
| SCHEMBL2224518 | 0.72 | USP2 (0.47) | SMN1; SMN2 | |
| SCHEMBL12144120 | 0.71 | HRH3 (0.38) | — | |
| SCHEMBL15637406 | 0.70 | GRM5 (0.38) | SMN1; SMN2GAA | |
| SCHEMBL4069044 | 0.68 | CTSB (0.38) | SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4247953 | 0.68 | GRM5 (0.37) | SMN1; SMN2GAA | |
| SCHEMBL21816817 | 0.65 | SMN1; SMN2 (0.39) | SMN1; SMN2GAA | |
| Hydrochloric Acid SCHEMBL4247948 | 0.64 | SMN1; SMN2 (0.38) | SMN1; SMN2GAA | |
| SCHEMBL22287128 | 0.64 | — | — | |
| SCHEMBL22609554 | 0.63 | SMN1; SMN2 (0.41) | SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109970764-A | A kind of synthetic method of (S) -1,1,5,5- tetramethyl dihydro-oxazole simultaneously [3,4-c] oxazole -3- ketone | 上海吉奉生物科技有限公司 | 2019-07-05 | — | — | CN | claimed |
| WO-2026101812-A1 | HIV INTEGRASE INHIBITORS FOR TREATMENT OF HIV INFECTION | MERCK SHARP & DOHME LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| EP-4651945-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2025-07-31 | — | — | US | disclosed |
| WO-2025034858-A1 | FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| CN-119233976-A | Modulators of c-MYC mRNA translation and their use in the treatment of cancer | 艾尼莫生物科技公司 | 2024-12-31 | — | — | CN | disclosed |
| WO-2024155836-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| WO-2024061211-A1 | LIPID COMPOUND FOR NUCLEIC ACID DELIVERY, AND RELATED USE AND MEDICAMENT COMPRISING SAME | 中国医学科学院基础医学研究所 | 2024-03-28 | — | — | WO | disclosed |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2023-09-14 | — | — | US | disclosed |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| EP-1289940-A2 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002090332-A2 | NOVEL AEYLHETEROALKYLAMINΕ DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-14 | — | — | WO | disclosed |
| EP-1194404-A1 | INHIBITORS OF ASPARTYL PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2002-04-10 | — | — | EP | disclosed |
| EP-1189873-A1 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | Lilly, S.A. (ES) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001092213-A2 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2000076961-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000075101-A1 | EXCITATORY AMINO ACID RECEPTOR MODULATORS | LILLY, S.A. (ES) | 2000-12-14 | — | — | WO | disclosed |
| EP-1019720-A1 | COMBINATORIAL PROCESS FOR PREPARING TETRAHYDROQUINOLINE LIBRARIES | ELI LILLY AND COMPANY (US) | 2000-07-19 | — | — | EP | disclosed |
| WO-1998027427-A1 | COMBINATORIAL PROCESS FOR PREPARING TETRAHYDROQUINOLINE LIBRARIES | ELI LILLY AND COMPANY (US) | 1998-06-25 | — | — | WO | disclosed |
| WO-1995028377-A1 | GUANIDINE COMPOUNDS AS REGULATORS OF NITRIC OXIDE SYNTHASE | ABBOTT LABORATORIES (US) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250243187-A1 | ANTI-VIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, HAVCR2 | SMN1; SMN2 239/4885GAA 37/4885CYP3A4 2328/4885 |
| US-20230286973-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | SMN1; SMN2 3954/4885GAA 485/4885CYP3A4 2885/4885 |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | LTB4R, C5, C3AR1 | SMN1; SMN2 4067/4885GAA 2481/4885CYP3A4 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.